The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab-Reference-Cited by-同舟云学术

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab

Published:2021-10 Issue: Volume:Volume 13 Page:8049-8056
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Furubayashi Nobuki^ORCID,Minato Akinori,Negishi Takahito,Sakamoto Naotaka,Song Yoohyun,Hori Yoshifumi,Tomoda Toshihisa^ORCID,Tamura Shingo,Kuroiwa Kentaro,Seki Narihito,Fujimoto Naohiro^ORCID,Nakamura Motonobu

Publisher

Informa UK Limited

Subject

Oncology

Reference24 articles.

1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

3. Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

4. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25);Clinical Genitourinary Cancer;2024-08

2. Machine Learning Model Based on the Neutrophil-to-Eosinophil Ratio Predicts the Recurrence of Hepatocellular Carcinoma After Surgery;Journal of Hepatocellular Carcinoma;2024-04

3. Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study;Anticancer Research;2024-03-27

4. Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie’s disease and are there any implications for a better understanding of its mechanisms?;Basic and Clinical Andrology;2023-12-19

5. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18